Home Page >
News and press releases >
News archive >
MucoVac2 HIV vaccine trial completes enrolment
MucoVac2 HIV vaccine trial
completes enrolment
23 August 2012
The MucoVac2
trial has completed enrolling participants. A total of 36 women
are taking part in the trial, which is an early phase HIV vaccine trial,
exploring different ways of giving a protein based vaccine,
including in a vaginal gel. The final results of the trial should
be available in 2013. The trial will provide preliminary
information on the safety of the vaccines, and how strongly the
immune system responds to it.
The study follows on from MucoVac1, in
which the genetically engineered protein was applied only in the
vagina. The schedule was very intense, with 9 applications over a
three week period, and so it was very disappointing that there were
no immune responses. Immunologists suspect this is because the body
needs to be primed first, so in MucoVac2, the intravaginal
applications follow a more conventional injection into the
muscle of the upper arm. Also, most vaccine regimens work on a
'prime and boost' principle, and the applications in MucoVac1 may
have been too close together.
The women taking part in MucoVac2 are
given vaccinations at the enrolment visit, and then 4 and 8 weeks
later. The women are split into 4 groups:
- standard dose protein prime,
intravaginal boost at 4 and 8 weeks
- three low dose protein vaccines in
the muscle
- three standard dose protein vaccines
in the muscle
- three standard dose protein vaccines dripped into the nose
Further information
